Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit
By Ben Glickman
Biofrontera is being sued by Sun Pharmaceutical, which alleges the company improperly promoted its Ameluz product.
The Woburn, Mass.-based dermatology-focused biopharmaceutical company said in a Tuesday regulatory filing it had been served the complaint, which was filed by Sun and connected companies on Sept. 13.
Biofrontera denies the claims and "intends to defend these matters vigorously."
The lawsuit alleges Biofrontera committed breach of contract and unfair trade practices and violated the Lanham Act, a trademark law.
"All claims stem from allegations that Biofrontera has promoted its Ameluz product in a manner that is inconsistent with its approved FDA labeling," Biofrontera said in the filing.
The case will be heard in the U.S. District Court for the District of New Jersey.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 03, 2023 18:28 ET (22:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?